Therapy in diabetic dyslipidemia

Key Result

Combination of saroglitazar and gemfibrozil has a good safety profile and may be a novel therapy for type 2 diabetes mellitus and diabetic dyslipidemia.

Key Points

• The aim is to evaluate the efficacy and safety of a combination of saroglitazar and gemfibrozil in treating diabetic dyslipidemia in T2DM.
• Evaluated the combination therapy of saroglitazar and gemfibrozil.
• Analyzed safety profiles and therapeutic effects.
• Compared the outcomes to existing treatments for diabetic dyslipidemia.
• The combination showed a good safety profile.
• Potentially fulfills unmet needs in managing diabetic dyslipidemia.
• Might provide new avenues for treatment in T2DM.